Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Notified -
Globe Newswire24-02-2025, 13:00
Founder Group Limited Secures US$2.36 million Contract for a 30MW Large Scale Solar Plant in Malaysia 10-09-2025, 19:30
